Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

The FDA has resolved the shortage of Wegovy and Ozempic, but companies like Hims and Hers may halt sales of compounded ...

Super Micro has until Tuesday to file delayed financial accounts or risk being delisted by the Nasdaq stock exchange, ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much ...

Hims is pivoting after drugmaker Novo Nordisk on Friday said the Food and Drug Administration has determined that the shortage of Wegovy and Ozempic has been resolved. Compounding its challenges in ...

Stock futures were falling on Tuesday as investors struggled to make up their minds about what escalating trade tensions would mean for markets. Trump said Monday that levies on imports from Canada ...

After the FDA removed semaglutide injection products from a shortage list, compounders like Hims have 60-90 days to stop ...

Hims & Hers Health (HIMS) has seen its shares decline over 17% in the past week since the U.S. Food and Drug Administration (FDA) announced ...

Hims & Hers Health reported fourth-quarter results on Monday that beat analysts’ expectations, but the stock sank in extended ...

Shares of Hims & Hers Health (HIMS) sank in after-hours trading after the healthcare company reported earnings for its fourth ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations ...

Hims & Hers Health Inc. shares lost as much as a fifth of their value in after-market trading Monday after the company said ...